Navigation Links
AstraZeneca Partners With Primary Health Care to Help Iowa Uninsured
Date:7/16/2009

ons for the uninsured in Iowa, creating accessibility to medications that are critical to their health."

The AZ&Me Prescription Savings program for healthcare facilities is available to non-profit organizations that have a licensed outpatient pharmacy or dispensary on site and meet other program criteria. Patients are eligible for AstraZeneca medicines through this program if they do not have prescription drug coverage and have a household income at or below $30,000 for an individual, or $60,000 for a family of four.

With this program, AstraZeneca builds on its more than 30-year history of helping patients afford the medicines they need.

To learn if your organization qualifies for the AZ&Me Prescription Savings program for healthcare facilities, please call 1-866-325-8198. Program specialists are available Monday through Friday between the hours of 9:00 AM and 5:00 PM ET.

Prescription savings programs are available regardless of which medications your doctors prescribe. To find out more about the more than 475 savings programs covering 2,500 medications, please visit www.pparx.org or call 1-888-4ppa-now (1-888-477-2669).

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: '/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease
2. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
3. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
4. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
5. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
6. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
7. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
8. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
9. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
10. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
11. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... of Americans, WASHINGTON, Dec. 5 Many of ... treatment, HHS,Secretary Mike Leavitt said today in marking fulfillment ... community health centers., Health centers deliver primary and ... Charges for health care services at,health centers are set ...
... Dec. 5 One of the greatest fears ... Syndrome), but due to extreme,precautionary measures taken to ... are rising by surprising levels. After the introduction,of ... were reduced,significantly. However, during this same period, children ...
... more than 10 million Americans, Osteoarthritis of the knee ... disability among the elderly. While OA mainly affects ... age. A double-blind, placebo-controlled study published in the journal ... from the bark of the French maritime pine tree, ...
... For patients with dialysis-related anemia, the risk of death ... a period several monthsnot necessarily when they fluctuate over ... Journal of the American Society of Nephrology. , "Our ... mortality, beyond the absolute level of hemoglobin, may not ...
... Certification for Pharmacy Techs, 91% ... Support Standards in Every State, ... the,Pharmacy Technician Certification Board (PTCB) shows that Americans have,strong misperceptions ... in pharmacies. The poll results,released today at the American Society ...
... HILL, N.C., Dec. 5 As companies transform ... with the art of selling while maintaining a ... in facilitating the changeover,the manager/supervisor is one of ... In fact, call center leaders recommend reducing ...
Cached Medicine News:Health News:HHS Marks Expansion of 1200th Health Center, Meeting Key Bush Goal 2Health News:Infant Development Program from EASY Baby Takes On the Sixty-Percent Increase in Developmental Delays in Children 2Health News:Study shows pine bark naturally reduces osteoarthritis knee pain 2Health News:Study shows pine bark naturally reduces osteoarthritis knee pain 3Health News:Study questions impact of hemoglobin variations on mortality in dialysis patients 2Health News:Survey Shows Broad Support Among Americans for Pharmacy Technician Certification 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Bermuda, Dec. 16 Celtic Pharmaceutical Holdings L.P. ("Celtic ... preliminary analyses completed on the two double-blinded studies of XERECEPT ... edema, as well as an initial database lock on the ... , The results of these studies ...
... Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time ... MannKind Corporation (Nasdaq: MNKD ) will host ... 3 studies of AFRESA(TM), the company,s ultra rapid acting, inhaled insulin product, ... , , To participate in the live ...
Cached Medicine Technology:Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: